Wieslawa Blank-Liss

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest

Michaela Medová, Daniel M. Aebersold, Wieslawa Blank-Liss et al. · Genes & Cancer · 2010 · 70 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers

Pirus Ghadjar, Wieslawa Blank-Liss, Mathew Simcock et al. · Clinical & Experimental Metastasis · 2009 · 34 citations · Full text

Medicine, Molecular Genetics, Oncology +12

The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants

Michaela Medová, Benoît Pochon, Bruno Streit et al. · Molecular Cancer Therapeutics · 2013 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation

Dominic Leiser, Benoît Pochon, Wieslawa Blank-Liss et al. · FEBS Letters · 2014 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +15

Coupling of Mutated Met Variants to DNA Repair via Abl and Rad51

Suganthini S. Ganapathipillai, Michaela Medová, Daniel M. Aebersold et al. · Cancer Research · 2008 · 25 citations · Full text

Medicine, Cancer Biology, Oncology +17